9 results on '"Van Reet, Bert"'
Search Results
2. TCT-139 Timing of Complete Multivessel Revascularization in Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndrome
- Author
-
Elscot, Jacob, primary, Kakar, Hala, additional, Scarparo, Paola, additional, Dekker, Wijnand den, additional, Bennett, Johan, additional, Schotborgh, Carl, additional, van der Schaaf, René, additional, Sabate, Manel, additional, Moreno, Raul, additional, Ameloot, Koen, additional, van Bommel, Rutger, additional, Forlani, Daniele, additional, van Reet, Bert, additional, Esposito, Giovanni, additional, Dirksen, Maurits, additional, Ruifrok, Willem, additional, Everaert, Bert, additional, van Mieghem, Carlos, additional, Bermudez, Eduardo Pinar, additional, Alfonso, Fernando, additional, Cummins, Paul, additional, Lenzen, Mattie, additional, Brugaletta, Salvatore, additional, Daemen, Joost, additional, Boersma, Eric, additional, van Mieghem, Nicolas, additional, and Diletti, Roberto, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Timing of Complete Multivessel Revascularization in Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome.
- Author
-
Elscot, Jacob J., Kakar, Hala, Scarparo, Paola, den Dekker, Wijnand K., Bennett, Johan, Schotborgh, Carl E., van der Schaaf, René, Sabaté, Manel, Moreno, Raúl, Ameloot, Koen, van Bommel, Rutger J., Forlani, Daniele, Van Reet, Bert, Esposito, Giovanni, Dirksen, Maurits T., Ruifrok, Willem P.T., Everaert, Bert R.C., Van Mieghem, Carlos, Pinar, Eduardo, and Alfonso, Fernando
- Abstract
Complete revascularization of the culprit and all significant nonculprit lesions in patients with non–ST-segment elevation acute coronary syndrome (NSTE-ACS) and multivessel disease (MVD) reduces major adverse cardiac events, but optimal timing of revascularization remains unclear. This study aims to compare immediate complete revascularization (ICR) and staged complete revascularization (SCR) in patients presenting with NSTE-ACS and MVD. This prespecified substudy of the BIOVASC (Percutaneous Complete Revascularization Strategies Using Sirolimus Eluting Biodegradable Polymer Coated Stents in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease) trial included patients with NSTE-ACS and MVD. Risk differences of the primary composite outcome of all-cause mortality, myocardial infarction (MI), unplanned ischemia-driven revascularization (UIDR), or cerebrovascular events and its individual components were compared between ICR and SCR at 1 year. The BIOVASC trial enrolled 1,525 patients; 917 patients presented with NSTE-ACS, of whom 459 were allocated to ICR and 458 to SCR. Incidences of the primary composite outcome were similar in the 2 groups (7.9% vs 10.1%; risk difference 2.2%; 95% CI: −1.5 to 6.0; P = 0.15). ICR was associated with a significant reduction of MIs (2.0% vs 5.3%; risk difference 3.3%; 95% CI: 0.9 to 5.7; P = 0.006), which was maintained after exclusion of procedure-related MIs occurring during the index or staged procedure (2.0% vs 4.4%; risk difference 2.4%; 95% CI: 0.1 to 4.7; P = 0.032). UIDRs were also reduced in the ICR group (4.2% vs 7.8%; risk difference 3.5%; 95% CI: 0.4 to 6.6; P = 0.018). ICR is safe in patients with NSTE-ACS and MVD and was associated with a reduction in MIs and UIDRs at 1 year. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Timing of Complete Multivessel Revascularization in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome
- Author
-
Elscot, Jacob Joseph, primary, Kakar, Hala, additional, Scarparo, Paola, additional, Den Dekker, Wijnand K, additional, Bennett, Johan R, additional, Schotborgh, Carl E, additional, van der Schaaf, Rene J, additional, Sabaté, Manel, additional, Moreno, Raúl, additional, Ameloot, Koen, additional, van Bommel, Rutger J, additional, Forlani, Daniele, additional, Van Reet, Bert, additional, Esposito, Giovanni, additional, Dirksen, Maurits Theodoor, additional, Ruifrok, Willem P.T., additional, Everaert, Bert R.C., additional, Van Mieghem, Carlos, additional, Pinar-Bermúdez, Eduardo, additional, Alfonso, Fernando, additional, Cummins, Paul, additional, Lenzen, Mattie J, additional, Brugaletta, Salvatore, additional, Daemen, Joost, additional, Boersma, Eric, additional, Van Mieghem, Nicolas M., additional, and Diletti, Roberto, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Assessing the landscape of percutaneous coronary chronic total occlusion treatment in Belgium and Luxembourg
- Author
-
Maeremans, Joren, Kayaert, Peter, Bataille, Yoann, Bennett, Johan, Ungureanu, Claudiu, Haine, Steven, Vandendriessche, Tom, Sonck, Jeroen, Scott, Benjamin, Coussement, Patrick, Dendooven, Daniël, Pereira, Bruno, Frambach, Peter, Janssens, Luc, Debruyne, Philippe, Van Mieghem, Carlos, Barbato, Emanuele, Cornelis, Kristoff, Stammen, Francis, De Vroey, Frederic, Vercauteren, Steven, Drieghe, Benny, Aminian, Adel, Debrauwere, Jan, Carlier, Stephane, Coosemans, Mark, Van Reet, Bert, Vandergoten, Peter, Dens, Jo Andre, (On behalf of the BWGCTO Investigators), Cardio-vascular diseases, Clinical sciences, Cardiology, Internal Medicine Specializations, Vrije Universiteit Brussel, Maeremans, Joren, Kayaert, Peter, Bataille, Yoann, Bennett, Johan, Ungureanu, Claudiu, Haine, Steven, Vandendriessche, Tom, Sonck, Jeroen, Scott, Benjamin, Coussement, Patrick, Dendooven, Daniël, Pereira, Bruno, Frambach, Peter, Janssens, Luc, Debruyne, Philippe, Van Mieghem, Carlo, Barbato, Emanuele, Cornelis, Kristoff, Stammen, Franci, De Vroey, Frederic, Vercauteren, Steven, Drieghe, Benny, Aminian, Adel, Debrauwere, Jan, Carlier, Stéphane, Coosemans, Mark, Van Reet, Bert, Vandergoten, Peter, and Dens, Jo Andre
- Subjects
Male ,medicine.medical_specialty ,Percutaneous ,Luxembourg ,medicine.medical_treatment ,Population ,030204 cardiovascular system & hematology ,Total occlusion ,03 medical and health sciences ,0302 clinical medicine ,Percutaneous Coronary Intervention ,Belgium ,medicine ,Journal Article ,Humans ,030212 general & internal medicine ,Registries ,education ,Adverse effect ,chronic total occlusion ,education.field_of_study ,business.industry ,Percutaneous coronary intervention ,Mean age ,General Medicine ,Middle Aged ,Surgery ,Dissection ,Treatment Outcome ,Conventional PCI ,Female ,Human medicine ,Cardiology and Cardiovascular Medicine ,business ,in-hospital outcomes - Abstract
Background: Important developments in materials, devices, and techniques have improved outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and resulted in a growing interest in CTO-PCI. The Belgian Working Group on Chronic Total Occlusions (BWGCTO) working group aims to assess the evolution within the CTO-PCI landscape over the next years. Methods: From May 2016 onwards, patients undergoing CTO-PCI were included in the BWGCTO registry by 15 centres in Belgium and Luxemburg. Baseline, angiographic, and procedural data were collected. Here, we report on the one-year in-hospital outcomes. Results: Over the course of one year, 411 procedures in 388 patients were included with a mean age of 64 ± 11 years. The majority were male (81%). Relatively complex CTOs were treated (Japanese CTO score =2.2 ± 1.2) with a high procedure success rate (82%). Patient- and lesion-wise success rates were 83 and 85%, respectively. Major adverse in-hospital events were acceptably low (3.4%). Antegrade wire escalation technique was applied most frequently (82%). On the other hand, antegrade dissection and re-entry and retrograde strategies were more frequently applied in higher volume centres and successful for lesions with higher complexity. Conclusion: Satisfactory procedural outcomes and a low rate of adverse events were obtained in a complex CTO population, treated by operators with variable experience levels. Antegrade wire escalation was the preferred strategy, regardless of operator volume.
- Published
- 2017
6. Assessing the landscape of percutaneous coronary chronic total occlusion treatment in Belgium and Luxembourg: the Belgian Working Group on Chronic Total Occlusions (BWGCTO) registry
- Author
-
Maeremans, Joren, Kayaert, Peter, Bataille, Yoann, Bennett, Johan, Ungureanu, Claudiu, Haine, Steven, Vandendriessche, Tom, Sonck, Jeroen, Scott, Benjamin, Coussement, Patrick, Dendooven, Daniël, Pereira, Bruno, Frambach, Peter, Janssens, Luc, Debruyne, Philippe, Van Mieghem, Carlos, Barbato, Emanuele, Cornelis, Kristoff, Stammen, Francis, De Vroey, Frederic, Vercauteren, Steven, Drieghe, Benny, Aminian, Adel, Debrauwere, Jan, Carlier, Stéphane, Coosemans, Mark, Van Reet, Bert, Vandergoten, Peter, and Dens, Jo Andre
- Abstract
AbstractBackground:Important developments in materials, devices, and techniques have improved outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and resulted in a growing interest in CTO-PCI. The Belgian Working Group on Chronic Total Occlusions (BWGCTO) working group aims to assess the evolution within the CTO-PCI landscape over the next years.Methods:From May 2016 onwards, patients undergoing CTO-PCI were included in the BWGCTO registry by 15 centres in Belgium and Luxemburg. Baseline, angiographic, and procedural data were collected. Here, we report on the one-year in-hospital outcomes.Results:Over the course of one year, 411 procedures in 388 patients were included with a mean age of 64 ± 11 years. The majority were male (81%). Relatively complex CTOs were treated (Japanese CTO score =2.2 ± 1.2) with a high procedure success rate (82%). Patient- and lesion-wise success rates were 83 and 85%, respectively. Major adverse in-hospital events were acceptably low (3.4%). Antegrade wire escalation technique was applied most frequently (82%). On the other hand, antegrade dissection and re-entry and retrograde strategies were more frequently applied in higher volume centres and successful for lesions with higher complexity.Conclusion:Satisfactory procedural outcomes and a low rate of adverse events were obtained in a complex CTO population, treated by operators with variable experience levels. Antegrade wire escalation was the preferred strategy, regardless of operator volume.
- Published
- 2018
- Full Text
- View/download PDF
7. Auto-intoxication with flecainide and quinapril
- Author
-
VAN REET, Bert, primary and DENS, Joseph, additional
- Published
- 2006
- Full Text
- View/download PDF
8. Early surgical repair of an acute post-infarction left ventricular pseudoaneurysm complicated by second pseudoaneurysm formation.
- Author
-
WOLF, Michael, VERMEERSCH, Paul, VAN REET, Bert, and VAN DEN BRANDEN, Frank L. J.
- Published
- 2012
- Full Text
- View/download PDF
9. Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
- Author
-
De Cock E, Kautbally S, Timmermans F, Bogaerts K, Hanet C, Desmet W, Gurné O, Vranckx P, Hiltrop N, Dujardin K, Vanduynhoven P, Vermeersch P, Pirlet C, Hermans K, Van Reet B, Ferdinande B, Aminian A, Dewilde W, Guédès A, Simon F, De Roeck F, De Vroey F, Jukema JW, Sinnaeve P, and Buysschaert I
- Abstract
Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of CAD and recurrent events. To date, there is no specific anti-inflammatory medicine available with proven effective, cost-efficient, and favorable benefit-risk profile, except for colchicine. Initial studies with colchicine have sparked major interest in targeting atherosclerotic events with anti-inflammatory agents, but further studies are warranted to enforce the role of colchicine role as a major treatment pillar in CAD. Given colchicine's low cost and established acceptable long-term safety profile, confirming its efficacy through a pragmatic trial holds the potential to significantly impact the global burden of cardiovascular disease. The COL BE PCI trial is an investigator-initiated, multicenter, double-blind, event-driven trial. It will enroll 2,770 patients with chronic or acute CAD treated with percutaneous coronary intervention (PCI) at 19 sites in Belgium, applying lenient in- and exclusion criteria and including at least 30% female participants. Patients will be randomized between 2 hours and 5 days post-PCI to receive either colchicine 0.5 mg daily or placebo on top of contemporary optimal medical therapy and without run-in period. All patients will have baseline hsCRP measurements and a Second Manifestations of Arterial Disease (SMART) risk score calculation. The primary endpoint is the time from randomization to the first occurrence of a composite endpoint consisting of all-cause death, spontaneous non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization. The trial is event-driven and will continue until 566 events have been reached, providing 80% power to detect a 21 % reduction in the primary endpoint taking a premature discontinuation of 15% into account. We expect a trial duration of approximately 44 months. The COL BE PCI Trial aims to assess the effectiveness and safety of administering low-dose colchicine for the secondary prevention in patients with both chronic and acute coronary artery disease undergoing PCI. Trial registration: ClinicalTrials.gov: NCT06095765., Competing Interests: Declaration of competing interest The authors have no conflict of interest related to the content of this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.